Co-infection with Mycobacterium tuberculosis is the leading cause of death in individuals
infected with HIV-1. It has long been known that HIV-1 infection alters the course of M …

Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a
global population of more than 35 million people living with HIV, there is intense interest in …

The development of persistent cellular reservoirs of latent human immunodeficiency virus
(HIV) is a critical obstacle to viral eradication since viral rebound takes place once anti …

Brain microglia (MG) may serve as a human immunodeficiency virus 1 (HIV) reservoir and
ignite rebound viremia following cessation of antiretroviral therapy (ART), but they have yet …

Human immunodeficiency virus type 1 (HIV-1) eradication is prevented by the establishment
on infection of cellular HIV-1 reservoirs that are not fully characterized, especially in genital …

In people living with HIV (PLWH) who are failing or unable to access combination
antiretroviral therapy (cART), monocytes and macrophages are important drivers of …

Despite years of fully suppressive antiretroviral therapy (ART), HIV persists in its hosts and is
never eradicated. One major barrier to eradication is that the virus infects multiple cell types …

Of the 13 known independent zoonoses of simian immunodeficiency viruses to humans,
only one, leading to human immunodeficiency virus (HIV) type 1 (M) has become pandemic …

Abstract Germ-free (GF) mice, which are depleted of their resident microbiota, are the gold
standard for exploring the role of the microbiome in health and disease; however, they are of …

In persons living with HIV-1 (PLWH) who start antiretroviral therapy (ART), plasma virus
decays in a biphasic fashion to below the detection limit. The first phase reflects the short …